ClinicalTrials.gg
CompletedNCT07079540X842Updated Jul 23, 2025

The Phase III Clinical Trial of X842 Capsules for Reflux Esophagitis

A Phase 3 interventional study of X842 and X842 Placebo in Reflux Esophagitis, sponsored by Jiangsu Sinorda Biomedicine Co., Ltd. Completed at 53 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-07-23.

Sponsored by Jiangsu Sinorda Biomedicine Co., Ltd · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years after the study started (first participant enrolled Jun 2021, registered Jul 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
380
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies in Esophagitis, Peptic with a site in China — 8 open to participants now, 8 under way, 2 of them phase 3. Esophagitis, Peptic · China.

Enrollment
2nd of 15
380 · median 90
Started
2021
with 1 other
Phase 3
4 of 18
2 open now
Registered
15th of 18
by date
Lead sponsor
3 of 18
Jiangsu Sinorda Biomedicine Co., Ltd

Among the 18 studies in Esophagitis, Peptic with a site in China, this one is the 2nd largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2021, is one of 4 in phase 3, and was the 15th registered.

Esophagitis, Peptic

83 studies on the registry are indexed under Esophagitis, Peptic; 16 are open to participants now.

Browse Esophagitis, Peptic studies →

Open to participants now

8 of the 18 studies in Esophagitis, Peptic with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 8 Esophagitis, Peptic studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Esophagitis, Peptic with a site in China, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of X842 Capsules 50 mg compared to Lansoprazole Enteric Capsules for the treatment of reflux esophagitis, and to characterize the population pharmacokinetics of X842 capsules in this patient population.

Read the detailed description

This study uses a multicenter, randomized, double-blind, double-dummy, active-controlled parallel-group, non-inferiority design to compare the efficacy and safety of X842 capsules (50 mg) in the treatment of reflux esophagitis over 4 to 8 weeks in comparison with lansoprazole enteric-coated capsules(30 mg) . Additionally, the population pharmacokinetics characteristics of X842 capsules in patients with reflux esophagitis is observed.

03

Conditions studied

  • Reflux Esophagitis

Browse trials for

Keywords

  • Reflux Esophagitis
  • X842
  • Population Pharmacokinetics, PopPK
  • Lansoprazole
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females, 18 years ≤ age ≤ 75 years;
  2. Within 7 days prior to randomization, the subjects are endoscopically diagnosed with reflux esophagitis from Los Angeles (LA) grade A to D (notes: the percent of the subjects with LA grade A of RE should be no more than 20% of the all subjects who are planned to be enrolled in the study);
  3. Subjects who can independently complete the subject diary cards;
  4. Subjects fully understand the trial contents, participate in the trial voluntarily, and sign the forms.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who receive X842 capsules or other P-CAB drugs in previous clinical studies;
  2. Subjects known to be allergic to X842 capsules or lansoprazole enteric-coated capsules, or relevant of X842 capsules or lansoprazole enteric-coated capsules, such as lactose, microcrystalline cellulose, croscarmellose sodium, sodium dodecyl sulfate, sodium stearyl fumarate, and silicon dioxide;
  3. Subjects unable to receive upper gastrointestinal endoscopy;
  4. Endoscopic examination revealed concomitant diseases potentially affecting the esophagus, excluding hiatal hernia, and excluding Barrett's esophagus with metaplastic columnar epithelium that either does not involve the entire esophageal circumference or is short-segment (\< 3 cm in length).
  5. Patients with rheumatic/ diseases potentially affecting esophageal motility (e.g., scleroderma, undifferentiated connective tissue disease), or those with a history of esophageal radiotherapy or cryotherapy;
  6. Subjects who have acute upper gastrointestinal hemorrhage within 4 weeks prior to enrollment;
  7. Subjects with active peptic ulcer discovered during upper gastrointestinal endoscopy, or subjects with suspicious or definite ;
  8. Subjects known to have Zollinger-Ellison syndrome or inflammatory bowel disease (IBD);
  9. Subjects with history of surgery affecting the structure or function of the esophagus, stomach, or duodenum, or surgery altering gastric acid secretion.
  10. Subjects who plan to undergo surgical procedures during the study period that may alter gastric acid secretion (e.g., abdominal surgery, vagotomy, or craniectomy).
  11. Subjects with a history of malignancies within 5 years prior to screening (a subject can participate in the study if his /her skin basal cell carcinoma or carcinoma in situ of uterine cervix has been cured);
  12. Subjects with concomitant serious diseases of central nervous system, cardiovascular system, respiratory system, liver, kidney, gastrointestinal tract, urinary system, endocrine system, or hematological system, and the investigator thinks these diseases may mix the study results up or affect the safety of the subject;
  13. Laboratory test results at screening showing that or AST is larger than 1.5 times of the , or kidney function index Cr is larger than the upper limit of normal (a re-examination is permitted in the study, and subjects will be excluded if they still fail to meet the inclusion criteria);
  14. Subjects who use of therapeutic doses of GERD medications within 7 days prior to randomization, eg. proton pump inhibitors (PPIs), P-CABs, histamine2 receptor antagonists (H2RAs), or gastric mucosal protectors (except hydrotalcite), prokinetic drugs, and traditional Chinese medicines;
  15. Subjects who chronically use non-steroidal anti-inflammatory drug (including cyclooxygenase-2 inhibitor), anti- drug (such as aspirin and clopidogrel), or anticoagulant (such as Warfarin) prior to randomization, and can not stop the medication during the trial;
  16. At screening, subjects with abnormalities, including serious arrhythmia, multifocal ventricular premature complexes, grade II or above atrioventricular block, and prolongation of the Q-Tc interval (≥450 ms in males and QTc≥470 ms in females);
  17. Subjects who are using atazanavir sulfate or ripivirin hydrochloride at screening;
  18. Subjects with a history of long-term abuse of drug or alcohol within 6 months prior to screening;
  19. Female subjects with known pregnancy, those in breast-feeding period, or those who are planned to become pregnant during the trial. At the investigator's discretion, women of childbearing age who cannot use a medically-proven and reliable method of from signing the forms to 4 weeks after the last dose of the study;
  20. Subjects who participate in other drug/medical device clinical studies and use the drug/medical device within 3 months prior to randomization;
  21. Subjects who are considered unsuitable for participating in this trial by investigators.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
380 participants (actual)

Study arms

  • Experimental
    X842 50mg QD

    X842 50 mg, capsule, orally, once daily and lansoprazole placebo-matching capsule, orally, once daily up to 4 to 8 weeks.

    Drug: X842 · Drug: Lansoprazole Placebo

  • Active comparator
    lansoprazole 30mg QD

    Lansoprazole 30 mg, capsule, orally, once daily and X842 placebo-matching capsule, orally, once daily up to 4 weeks.

    Drug: X842 Placebo · Drug: Lansoprazole

Interventions

  • DrugX842

    X842 capsules

    Also known as: X842 capsules

  • DrugX842 Placebo

    X842 placebo-matching capsules

  • Lansoprazole capsules

    Also known as: Lansoprazole capsules

  • DrugLansoprazole Placebo

    Lansoprazole placebo-matching capsules

06

What researchers measure

Primary outcomes

  1. Proportion of Subjects Whose Reflux Esophagitis is Cured as Confirmed by Endoscopy at Week 8

    Healing of reflux esophagitis is defined as endoscopic confirmation of resolved esophagitis (absence of esophageal mucosal breaks) in subjects.

    Time frame: 8 weeks

Secondary outcomes

  1. Proportion of Subjects Whose Reflux Esophagitis is Cured as Confirmed by Endoscopy at Week 4

    Healing of reflux esophagitis is defined as endoscopic confirmation of resolved esophagitis (absence of esophageal mucosal breaks) in subjects.

    Time frame: 4 weeks

  2. Improvement rate in the frequency and severity of individual clinical symptoms (heartburn, regurgitation) of reflux esophagitis at Weeks 2, 4, and 8 after treatment initiation.

    Improvement in the frequency of clinical symptom occurrence: Defined as subjects whose symptom frequency score before treatment was ≥1 point had a reduction of ≥1 point after treatment compared to before treatment. Improvement in the severity of clinical symptoms: Defined as a reduction of ≥1 point in the symptom severity score of subjects with a score of ≥1 point before treatment after treatment compared to before treatment.

    Time frame: 2,4,8 weeks

  3. Response rates for individual symptom domains (heartburn, regurgitation) in reflux esophagitis at Weeks 2, 4, and 8 post-baseline.

    Resolution of individual clinical symptoms: defined as the achievement of score 0 in both severity and frequency for symptoms with baseline scores ≥1.

    Time frame: 2.4.8 weeks

  4. Overall symptomatic resolution rate for reflux esophagitis at Weeks 2, 4, and 8

    Overall Clinical Symptom Resolution: Defined as the achievement of a score of 0 (i.e., complete disappearance) for all symptoms of reflux esophagitis in subjects with any individual symptom score ≥1 at baseline.

    Time frame: 2,4,8 weeks

  5. Change in serum gastrin levels from baseline at Weeks 4 and 8 of treatment

    Serum gastrin testing will be conducted at the central laboratory. The change between the serum gastrin values collected at Weeks 4 and 8 relative to baseline.

    Time frame: 4, 8 weeks

  6. Number of Subjects Reporting Who Had One or More Treatment-emergent Adverse Event (TEAE)

    Adverse event is defined as any adverse medical event that is observed in a subject who is receiving a drug treatment or in a clinical study, and that does not necessarily have a causal relationship with the treatment.

    Time frame: up to 8 weeks

  7. Number of Subjects With Markedly Abnormal Clinical Laboratory assessment of blood serum Number of Subjects With Markedly Abnormal Clinical Laboratory assessment of blood serum

    Number of subjects with any markedly abnormal values in laboratory tests of blood serum collected throughout study is reported.

    Time frame: up to 8 weeks

  8. Number of Subjects With Markedly Abnormal Clinical Laboratory assessment of blood

    Number of subjects with any markedly abnormal values in laboratory tests of blood collected throughout study is reported.

    Time frame: up to 8 weeks

  9. Number of Subjects With Markedly Abnormal Clinical Laboratory assessment of urine

    Number of subjects with any markedly abnormal values in laboratory tests of urine collected throughout study is reported.collected throughout study is reported.

    Time frame: up to 8 weeks

  10. Number of Subjects With Markedly Abnormal Electrocardiogram (ECG) Findings

    The investigator or the sub-investigator interpreted the ECG using one of the following categories: "within normal limits", "abnormal but not clinically significant", or "abnormal and clinically significant"

    Time frame: up to 8 weeks

  11. Vital signs

    Blood pressure, respiration, heart rate and body temperature were evaluated at each visit during the screening period and the double-blind treatment period

    Time frame: up to 8 weeks

  12. Pharmacokinetic evaluation

    Quantification of plasma concentrations of X842 and its metabolites to characterize the population pharmacokinetic profile of X842 capsules in GERD patients.

    Time frame: up to 8 weeks

07

Study locations

53 sites
  • Liuan People's Hospital
    Liu‘an, Anhui 237016, China
  • Xuancheng People's Hospital
    Xuancheng, Anhui 242000, China
  • The 900th Hospital of the Joint Logistic Support Force of the People's Liberation Army of China
    Fuzhou, Fujian 350001, China
  • The First Hospital of Lanzhou University
    Lanzhou, Gansu 730000, China
  • Nanfang Hospital, Southern Medical University
    Guangzhou, Guangdong 510515, China
  • Huizhou Central People's Hospital
    Huizhou, Guangdong 516000, China
  • Jiangmen Central Hospital
    Jiangmen, Guangdong 529000, China
  • Meizhou People's Hospital
    Meizhou, Guangdong 514031, China
  • Peking University Shenzhen Hospital
    Shenzhen, Guangdong 518036, China
  • Liuzhou Worker's Hospital
    Liuzhou, Guangxi 545005, China
  • The Second Nanning People's Hospital
    Nanjing, Guangxi 530031, China
  • The Affiliated Hospital of Guzihou Medical University
    Guiyang, Guizhou 550004, China
  • Affiliated Hospital of Zunyi Medical University
    Zunyi, Guizhou 563000, China
  • Hainan General Hospital
    Haikou, Hainan 570311, China
  • Cangzhou Central Hospital
    Cangzhou, Hebei 061000, China
  • Henan Provincial People's Hospital
    Zhengzhou, Henan 450003, China
  • Zhengzhou People's Hospital
    Zhengzhou, Henan 450003, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450052, China
  • Taihe Hospital of Shiyan City
    Shiyan, Hubei 442700, China
  • Affiliated Union Hospital, Tongji Medical College of Huazhong University of Science & Technology
    Wuhan, Hubei 430022, China
  • Xiangya Hospital Central South University
    Changsha, Hunan 410008, China
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan 410011, China
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan, China
  • The First People's Hospital of Chenzhou City
    Chenzhou, Hunan 423000, China
  • The Second Affiliated Hospital of South China University
    Hengyang, Hunan 421001, China
  • The First Affiliated Hospital Of University Of South China
    Hengyang, Hunan, China
  • Huai 'an First People's Hospital
    Huaian, Jiangsu 223300, China
  • The First People's Hospital of Lianyungang
    Lianyungang, Jiangsu 222061, China
  • Zhongda Hospital of Southeast University
    Nanjing, Jiangsu 210000, China
  • Wuxi People's Hospital
    Wuxi, Jiangsu 214023, China
  • Affiliated Hospital of Yangzhou University(Yangzhou First People's Hospital)
    Yangzhou, Jiangsu 225003, China
  • Affiliated Hospital of Jiangsu University
    Zhenjiang, Jiangsu 212013, China
  • The Second Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
  • Pingxiang People's Hospital
    Pingxiang, Jiangxi 337099, China
  • The Second Hospital of Jilin University
    Changchun, Jinlin 130022, China
  • The First Hospital of Jilin University
    Changchun, Jinlin 130031, China
  • Shengjing Hospital Of China Medical University
    Shenyang, Liaoning 110134, China
  • General Hospital of Ningxia Medical University
    Yinchuan, Ningxia 750004, China
  • Affiliated Hospital of Binzhou Medical University
    Binzhou, Shandong 256600, China
  • Jinan Central Hospital
    Ji'nan, Shandong 250013, China
  • The Affiliated Hospital of Qingdao University
    Qingdao, Shandong 266000, China
  • Zigong Fourth People's Hospital
    Zigong, Sichuan 643000, China
  • The Second Affiliated Hospital Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310009, China
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang 325000, China
  • The Second Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang 325027, China
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, 100050, China
  • Peking University Third Hospital
    Beijing, 100091, China
  • Beijing Luhe Hospital Capital Medical University
    Beijing, 101100, China
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, 400016, China
  • Chongqing University Three Gorges Hospital
    Chongqing, 404000, China
  • Tongji Hospital Affiliated to Tongji University
    Shanghai, 200065, China
  • Shanghai East Hospital
    Shanghai, 200120, China
  • Nankai Hospital of Tianjin City
    Tianjin, 300100, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in Jul 2022, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2025
First posted
Jul 23, 2025
StartActual
Jun 24, 2021
Primary completionActual
Jul 27, 2022
CompletionActual
Dec 1, 2022
Last update
Jul 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07079540
Lead sponsor
Jiangsu Sinorda Biomedicine Co., Ltd
Responsible party
Sponsor
First posted
Jul 23, 2025
Start date
Jun 24, 2021
Primary completion
Jul 27, 2022
Completion
Dec 1, 2022
Last update
Jul 23, 2025

Study contacts

Pingsheng Hu, Ph.D
study chair · Jiangsu Sinorda Biomedicine Co., Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linaprazan glurate

Start the discussion